CHEPLAPHARM Arzneimittel GmbH


This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.


Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

02nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit


The latest from CHEPLAPHARM

Changes of CHEPLAPHARM Management Board per March

Greifswald – 1st March 2021

CHEPLAPHARM is delighted to herewith inform of the change of its board of management.

With effect as of 1st of March 2021 Edeltraud Lafer, COO since 2014, will hand over her position to Patrick König, former Director Global Sales of CHEPLAPHARM. At the same time Edeltraud Lafer will take over the role as Co-CEO besides Sebastian Braun to manage the company in form of a dual leadership.

In this way, CHEPLAPHARM wants to clearly place its core competence, the business development, in the focus of the company's future business.

Investor Relations topics

Back to top expand_less